(Reuters) – Moderna Inc on Thursday cut the annual sales forecast for its COVID-19 vaccine to between $18 billion and $19 billion from $21 billion, citing short-term supply constraints.
It did not disclose further details on the supply issues. The vaccine maker said deliveries for some contracts are now expected next year.
It reported sales of $3.40 billion in the third quarter, missing Wall Street estimates of $3.53 billion.
(Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)
